Intervention Review

You have free access to this content

Magnesium sulphate for women at term for neuroprotection of the fetus

  1. Thuy-My N Nguyen1,
  2. Caroline A Crowther1,*,
  3. Dominic Wilkinson2,
  4. Emily Bain3

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 28 FEB 2013

Assessed as up-to-date: 10 DEC 2012

DOI: 10.1002/14651858.CD009395.pub2


How to Cite

Nguyen TMN, Crowther CA, Wilkinson D, Bain E. Magnesium sulphate for women at term for neuroprotection of the fetus. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD009395. DOI: 10.1002/14651858.CD009395.pub2.

Author Information

  1. 1

    The University of Adelaide, ARCH: Australian Research Centre for Health of Women and Babies, Discipline of Obstetrics and Gynaecology, Adelaide, South Australia, Australia

  2. 2

    Women's and Children's Hospital, University of Adelaide, Discipline of Obstetrics and Gynecology, North Adelaide, SA, Australia

  3. 3

    Discipline of Obstetrics and Gynaecology, The University of Adelaide, ARCH: Australian Research Centre for Health of Women and Babies, Adelaide, Australia

*Caroline A Crowther, ARCH: Australian Research Centre for Health of Women and Babies, Discipline of Obstetrics and Gynaecology, The University of Adelaide, Women's and Children's Hospital, 72 King William Road, Adelaide, South Australia, 5006, Australia. caroline.crowther@adelaide.edu.au.

Publication History

  1. Publication Status: New
  2. Published Online: 28 FEB 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Witlin 1997 {published data only}
  • Witlin AG, Friedman SA, Sibai BM. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: A randomised, double-blind, placebo-controlled trial. American Journal of Obstetrics and Gynecology 1997;176(3):623-7.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Magann 1995 {published data only}
  • Magann EF, Norman PF, Bass JD, Chauhan SO, Martin JN Jr, Morrison JC. Acute tocolysis for suspected intrapartum fetal distress: maternal effects of terbutaline versus magnesium sulfate. International Journal of Obstetric Anesthesia 1995;4:140-4.

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Blackwell 2001 {published and unpublished data}
  • Blackwell S. Effects of intrapartum magnesium sulfate therapy on fetal adrenal function: a randomised placebo-controlled trial [abstract]. American Journal of Obstetrics and Gynecology 2001;184(1):s138.
  • Blackwell SC, Hallak M, Hassan SS, Berry SM, Russel E, Sorokin Y. The effects of intrapartum magnesium sulfate therapy on fetal serum interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha at delivery: a randomised, placebo-controlled trial. American Journal of Obstetrics and Gynecology 2001;184(7):1320-3.
  • Blackwell SC, Hallak M, Hassan SS, Norman G, Poole-Bryant K, Steffy B, et al. Clinical chorioamnionitis is associated with a decreased maternal-fetal concentration gradient of ionized magnesium in patients receiving magnesium sulphate: a randomised study. American Journal of Obstetrics and Gynecology 2000;182(1 Pt 2):S103.
Chen 1995 {published and unpublished data}
Coetzee 1998 {published and unpublished data}
Livingston 2003 {published and unpublished data}
Magpie 2002 {published and unpublished data}
  • Magpie Trial Collaborative Group. Do women with preeclampsia,and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359:1877-90.
Moodley 1994 {published and unpublished data}
  • Moodley J, Moodley VV. Prophylactic anticonvulsant therapy in hypertensive crises of pregnancy - the need for a large randomized trial. Hypertension in Pregnancy 1994;13:245-52.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Australian Register 2009
  • ACPR Group. Report of the Australian Cerebral Palsy Register, Birth Years 1993-2003. Cerebral Palsy Institute, Dec 2009.
Blair 2006
Bracci 2003
Canterino 1999
  • Canterino JC, Verma UL, Visintainer PF, Figueroa R, Klein SA, Tejani NA. Maternal magnesium sulfate and the development of neonatal periventricular leucomalacia and intraventricular hemorrhage. Obstetrics & Gynecology 1999;93:396-402.
Conde-Agudelo 2009
  • Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks gestation: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology 2009;200:595-609.
Costantine 2011
  • Costantine MM, Drever M. Antenatal exposure to magnesium sulfate and neuroprotection in preterm infants. Obstetrics and Gynecology Clinics of North America 2011;38:351-66.
Crowther 2002
  • Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD001060]
Crowther 2003
  • Crowther CA, Hiller JE, Doyle LW, Haslam RR, for the Australian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA 2003;290(20):2669-76.
Cruz 2006
Dilenge 2001
Doyle 2009
  • Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD004661.pub3]
Duley 2010
Egger 1997
Finesmith 1997
  • Finesmith RB, Roche K, Yellin PB, Walsh KK, Shen C, Zeglis M, et al. Effect of magnesium sulfate on the development of cystic periventricular leukomalacia in preterm infants. American Journal of Perinatology 1997;14(5):303-7.
Gladstone 2010
  • Gladstone M. A review of the incidence and prevalence, types and aetiology of childhood cerebral palsy in resource-poor settings. Annals of Tropical Paediatrics 2010;30(3):181-96.
Grether 1998
  • Grether JK, Hoogstrate K, Walsh-Greene E, Nelson KB. Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. American Journal of Obstetrics and Gynecology 1998;178(1 Pt 1):1-6.
Harbord 2006
Higgins 2011
  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Jacobsson 2008
Jarvis 2006
Kimberlin 1998
  • Kimberlin DF, Hauth JC, Goldenberg RL, Bottoms SF, Iams JD, Mercer B, et al. The effect of maternal magnesium sulfate treatment on neonatal morbidity in < or = 1000-gram infants. American Journal of Perinatology 1998;15:635-41.
Lipsitz 1971
MacLennan 1999
Marret 2006
Marret 2007
Maulik 2005
  • Maulik D, Mishra OP, Delivoria-Papadopoulos M. Effect of post-hypoxic MgSO(4) administration in utero on Ca(2+)-influx and Ca(2+)/calmodulin kinase IV activity in cortical neuronal nuclei. Neuroscience Letters 2005;386(2):127-32.
Menon 2009
Mittendorf 2002
  • Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, et al. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. American Journal of Obstetrics and Gynecology 2001;185(6 Suppl):S151.
Nelson 1995
NHMRC 2010
  • The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child:National clinical practice guidelines. Adelaide: The University of Adelaide 2010.
RevMan 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Rouse 2008
Schendel 1996
  • Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA 1996;276(22):1805-10.
SOGC 2011
  • Magee L, Sawchuck D, Synnes A, von Dadelszen P, Magnesium Sulphate for Fetal Neuroprotection Consensus Committee. Society of Obstetricians and Gynaecologists of Canada Clinical Practice Guideline No. 258, May 2011. Magnesium sulphate for fetal neuroprotection. Journal of Obstetrics and Gynaecology Canada 2011;33(5):516–29.
Stanley 2000
  • Stanley F, Blair E, Alberman E. Cerebral Palsies: Epidemiology and Causal Pathways. Cambridge: Cambridge University Press, 2000.
Wu 2003
Wu 2009
  • Wu CS, Nohr EA, Bech BH, Vestergaard M, Catov JM, Olsen J. Health of children born to mothers who had preeclampsia: a population-based cohort study. American Journal of Obstetrics and Gynecology 2009;201(3):269-70.